TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31279028

Group type: EXPERIMENTAL
Intervention: Crisaborole 2% ointment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 21
Study: 31340023

Group type: EXPERIMENTAL
Intervention: PISCES alerts (software application for real-time clinical trial enrollment)
Number of subjects: 15626

Group type: COMPARATOR
Intervention: Before PISCES implementation (control group)
Number of subjects: 15626

Group type: EXPERIMENTAL
Intervention: After PISCES implementation (intervention group)
Number of subjects: 15626
Study: 28535772

Group type: EXPERIMENTAL
Intervention: Annual Physical Examination (APE) in urban elderly
Number of subjects: 3922

Group type: COMPARATOR
Intervention: Annual Physical Examination (APE) in rural elderly
Number of subjects: 3922

Group type: COMPARATOR
Intervention: Factors associated with APE use in rural elderly
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: Factors associated with APE use in urban elderly
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: Elderly covered by Urban Resident Basic Medical Insurance (URBMI) in urban areas
Number of subjects: 3922
Study: 26082611

Group type: EXPERIMENTAL
Intervention: Amlodipine orotate/olmesartan medoxomil 10/40 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amlodipine besylate/olmesartan medoxomil 10/40 mg
Number of subjects: 30
Study: 23697800

Group type: EXPERIMENTAL
Intervention: Refined calcium montmorillonite clay (UPSN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (calcium carbonate)
Number of subjects: 0
Study: 22025998

Group type: EXPERIMENTAL
Intervention: Long glass fiber‐reinforced posts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long metal screw posts
Number of subjects: 100
Study: 19694343

Group type: EXPERIMENTAL
Intervention: Symbiotic formulation containing Lactobacillus Paracasei B 20160
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17021425

Group type: EXPERIMENTAL
Intervention: 250 ml of diluted lemon juice (G4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 250 ml of whole milk (G3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 250 ml of water (G2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No action (G1)
Number of subjects: 80
Study: 15564189

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (HCD)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Conventional gauze dressing
Number of subjects: 693
Study: 10639609

Group type: EXPERIMENTAL
Intervention: Recombinant-methionyl human neurotrophin-3 (r-metHuNT3) at doses ranging from 3 to 500 microg/kg/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9299802

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7506158

Group type: EXPERIMENTAL
Intervention: Oral nimesulide 300 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral diclofenac 150 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Rectal nimesulide 400 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Rectal diclofenac 200 mg/day
Number of subjects: 64
Study: 3713394

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-convective nystagmus
Number of subjects: 22
Study: 30203153

Group type: EXPERIMENTAL
Intervention: MTX/UST combination therapy
Number of subjects: 196

Group type: COMPARATOR
Intervention: UST monotherapy
Number of subjects: 196
Study: 27507876

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 on day 1 of every 21-day cycle) plus gefitinib (250 mg/d)
Number of subjects: 195
Study: 24730621

Group type: EXPERIMENTAL
Intervention: Surgical periodontal therapy with initial scaling and root planing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Surgical periodontal therapy without initial scaling and root planing
Number of subjects: 24
Study: 22646067

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate oral solution
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19865076

Group type: EXPERIMENTAL
Intervention: bupropion HCl
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: practical group counseling (PGC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: pill placebo
Number of subjects: 54
Study: 17509314

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily until stone clearance or for a maximum of 30 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (daily until stone clearance or for a maximum of 30 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16194582

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 12352802

Group type: EXPERIMENTAL
Intervention: Two dose and fractional three dose schedules of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Three half-doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All dosing regimens of polyribosylribosyl phosphate-tetanus toxoid conjugate vaccine
Number of subjects: 73
Study: 9915318

Group type: EXPERIMENTAL
Intervention: Epidural alfentanil (400 microg bolus + a 400‐microg/h infusion for 2 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (computer-controlled infusion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epidural saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 12
Study: 7844365

Group type: EXPERIMENTAL
Intervention: Didanosine monotherapy or combination therapy with zidovudine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: QMC assay
Number of subjects: 109
Study: 2216216

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31095263

Group type: EXPERIMENTAL
Intervention: Personal Sound Amplification Product (PSAP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Basic Hearing Aid (HA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Premium Hearing Aid (HA)
Number of subjects: 56
Study: 28241133

Group type: EXPERIMENTAL
Intervention: Sertraline (intervention in a multicentre randomised placebo-controlled trial)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo (control in a multicentre randomised placebo-controlled trial)
Number of subjects: 470
Study: 25219348

Group type: EXPERIMENTAL
Intervention: 10-year intervention
Number of subjects: 979

Group type: COMPARATOR
Intervention: Control
Number of subjects: 979
Study: 23080373

Group type: EXPERIMENTAL
Intervention: Unsupported self-help CBT-I
Number of subjects: 479
Study: 21406101

Group type: EXPERIMENTAL
Intervention: Methyl-prednisolone (MPDN)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 19332455

Group type: EXPERIMENTAL
Intervention: Early eptifibatide (two boluses of 180 microg/kg administered 10 minutes apart, and a standard infusion for >= 12 hours before angiography)
Number of subjects: 9492

Group type: COMPARATOR
Intervention: Delayed eptifibatide (matching placebo infusion with provisional use after angiography)
Number of subjects: 9492

Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 9492

Group type: COMPARATOR
Intervention: Delayed eptifibatide
Number of subjects: 9492
Study: 17357577

Group type: EXPERIMENTAL
Intervention: Alpha dihydroergocryptine (10 mg tablets)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 15234134

Group type: EXPERIMENTAL
Intervention: Vitrectomy, cryotherapy, and either complete (n = 8) or partial (n = 16) fluid-gas exchange. Patients with complete fluid-gas exchange were kept in a prone position for 6 hours; partial fluid-gas exchange patients were kept in a supine position with head elevated for 12 hours.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Episcleral buckle, cryotherapy, and, in selected cases, external drainage of subretinal fluid.
Number of subjects: 33
Study: 11547705

Group type: EXPERIMENTAL
Intervention: Disease Management Assistance System (electronic adherence device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monthly educational session (control)
Number of subjects: 0
Study: 9429959

Group type: EXPERIMENTAL
Intervention: Educational interventions and self-assessment questionnaires relating to smoking cessation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine information
Number of subjects: 60
Study: 8272246

Group type: EXPERIMENTAL
Intervention: Filtral device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G120 M device
Number of subjects: 0

Group type: COMPARATOR
Intervention: All dialysers
Number of subjects: 0
Study: 3627593

Group type: EXPERIMENTAL
Intervention: Penile nerve block
Number of subjects: 30

Group type: COMPARATOR
Intervention: No anesthesia (Control)
Number of subjects: 30
Study: 29347946

Group type: EXPERIMENTAL
Intervention: Vibrotactile sensory augmentation during balance training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no sensory augmentation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 27742605

Group type: EXPERIMENTAL
Intervention: Narrative group (watched narrative cutscene before gameplay)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-narrative group (did not watch narrative cutscene)
Number of subjects: 40
Study: 25039978

Group type: EXPERIMENTAL
Intervention: Esomeprazole or AZD0865 (potent acid suppression treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-grade reflux oesophagitis (A or B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Frequent regurgitation at baseline
Number of subjects: 100
Study: 24376568

Group type: EXPERIMENTAL
Intervention: High Frequency electrical Stimulation (HFS)
Number of subjects: 19
Study: 19498450

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation using fibrin glue (Tisseel)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 8-0 vicryl sutures
Number of subjects: 70
Study: 18955430

Group type: EXPERIMENTAL
Intervention: Home-based training for three months with biweekly telephone monitoring
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 17032283

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (10^8 CFU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15042476

Group type: EXPERIMENTAL
Intervention: Disease specific instruments (BELP‐KF, DMLQ)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: EQ‐5D
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TTO
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 44

Group type: COMPARATOR
Intervention: DMLQ
Number of subjects: 44

Group type: COMPARATOR
Intervention: BELP‐KF
Number of subjects: 44
Study: 11401810

Group type: EXPERIMENTAL
Intervention: Charge data provided to residents
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Group decision making with charge data
Number of subjects: 23

Group type: COMPARATOR
Intervention: No charge data
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Charge data after ordering tests
Number of subjects: 23
Study: 9296893

Group type: EXPERIMENTAL
Intervention: t‐PA and PAI‐1 concentrations in patients with type II diabetes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 21
Study: 8513981

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (40 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (80 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study: 3695448

Group type: COMPARATOR
Intervention: Constant Amplitude (CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sinusoidally Modulated (SAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomly Modulated (RAM)
Number of subjects: 0
Study: 31870125

Group type: EXPERIMENTAL
Intervention: Multichannel applicator for HDR vaginal brachytherapy
Number of subjects: 11
Study: 28487318

Group type: EXPERIMENTAL
Intervention: Initial coronary CTA strategy
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1234
Study: 25549768

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH) or laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 164
Study: 22533516

Group type: EXPERIMENTAL
Intervention: Spiritual therapy intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (routine management and educational programs)
Number of subjects: 68
Study: 21362329

Group type: EXPERIMENTAL
Intervention: Low dose unfractionated heparin
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 607

Group type: COMPARATOR
Intervention: VTE incidence
Number of subjects: 607

Group type: COMPARATOR
Intervention: Mortality rate
Number of subjects: 607

Group type: COMPARATOR
Intervention: Medical disorders contributing to VTE
Number of subjects: 607
Study: 19731307

Group type: EXPERIMENTAL
Intervention: Standard dose rituximab (375 mg/m2 x 4)
Number of subjects: 20

Group type: COMPARATOR
Intervention: R-CVP (rituximab with cyclophosphamide, vincristine, and prednisone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Double dose rituximab (DDR)
Number of subjects: 20
Study: 16706755

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract (CRS) applied twice daily for 3 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tissue Nutrient Solution Recovery Complex (TNS) applied twice daily for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vitamin C (Vit C) cream applied twice daily for 3 months
Number of subjects: 32
Study: 15053698

Group type: EXPERIMENTAL
Intervention: Direct relations (auditory icons that use the sound made by the target event)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect relations (ecological, metaphorical, and random)
Number of subjects: 0
Study: 11397885

Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion infusion + heparin (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline infusion (control study; n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intensified insulin treatment after 3 months (n = 30)
Number of subjects: 30
Study: 9779369

Group type: COMPARATOR
Intervention: Healthy control subjects (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with achalasia (group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study: 7944453

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (IP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraaortic chemotherapy (IA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 3331044

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 210

Group type: COMPARATOR
Intervention: Amikacin plus piperacillin
Number of subjects: 210
Study: 29314705

Group type: EXPERIMENTAL
Intervention: Enhanced Homestead Food Production (EHFP)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Enhanced Homestead Food Production plus Aquaculture (EHFP + Aquaculture)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control
Number of subjects: 900
Study: 27689610

Group type: EXPERIMENTAL
Intervention: High intensity exercise rehabilitation
Number of subjects: 14
Study: 24490025

Group type: EXPERIMENTAL
Intervention: Sertindole (16-24 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 9

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 9
Study: 23137020

Group type: EXPERIMENTAL
Intervention: Fibrin pad
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 17
Study: 20728522

Group type: EXPERIMENTAL
Intervention: gp120/NefTat candidate HIV-1 vaccine with AS01(B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gp120/NefTat candidate HIV-1 vaccine with AS02(A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gp120/NefTat candidate HIV-1 vaccine with AS02(V)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gp120/NefTat candidate HIV-1 vaccine
Number of subjects: 0
Study: 18991469

Group type: EXPERIMENTAL
Intervention: LNX‐QR 8 mg tablet
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: LNX‐ST 8 mg tablet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 15825930

Group type: EXPERIMENTAL
Intervention: Strong argument with celebrity spokesperson
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strong argument with noncelebrity spokesperson
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weak argument with celebrity spokesperson
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weak argument with noncelebrity spokesperson
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inner-directed subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Argument strength (strong vs weak)
Number of subjects: 0
Study: 12887004

Group type: EXPERIMENTAL
Intervention: Bioabsorbable membrane (RXT group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bioactive glass (PG group)
Number of subjects: 12
Study: 11798692

Group type: EXPERIMENTAL
Intervention: Losec (40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aoke‐Changzhou No.4 Pharm (40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Omeprazole‐Sanye Pharm (40 mg)
Number of subjects: 18
Study: 8683228

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and fluorouracil (M‐‐>F)
Number of subjects: 1855

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 1855
Study: 1806728

Group type: EXPERIMENTAL
Intervention: Ramp time of 1.0 seconds
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ramp time of 3.5 seconds
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ramp time of 5.0 seconds
Number of subjects: 47
Study: 6348763

Group type: EXPERIMENTAL
Intervention: Steroids or chlorambucil given in alternate months for a cumulative period of six months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Supportive therapy (Control)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Steroids or chlorambucil
Number of subjects: 49
Study: 31373314

Group type: EXPERIMENTAL
Intervention: Education intervention on nutrition, hygiene, and stimulation
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 155
Study: 29703800

Group type: EXPERIMENTAL
Intervention: Text-based blood pressure monitoring
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care blood pressure check at prenatal clinic
Number of subjects: 206
Study: 27621394

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 25367235

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg administered 2 minutes before aortic declamping)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenously administered 15 minutes before release of aortic cross clamp)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lidocaine and Placebo (when ventricular fibrillation occurred)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Amiodarone (when ventricular fibrillation occurred)
Number of subjects: 86
Study: 22965962

Group type: EXPERIMENTAL
Intervention: (ziv‐)aflibercept 6 mg/kg IV + docetaxel 75 mg/m²
Number of subjects: 913

Group type: COMPARATOR
Intervention: Placebo + docetaxel 75 mg/m²
Number of subjects: 913
Study: 19826792

Group type: EXPERIMENTAL
Intervention: Double-blind paroxetine (DBPX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-blind paroxetine (SBPX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Double-blind placebo (DBPO)
Number of subjects: 30
Study: 16091055

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 477

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg on-demand
Number of subjects: 477
Study: 12590989

Group type: EXPERIMENTAL
Intervention: Tailored interventions (telephone counseling, in-person counseling, physician letter, combinations of telephone with letter and in-person with letter)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Combination of in-person with physician letter
Number of subjects: 773

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Tailored interventions
Number of subjects: 773
Study: 10496434

Group type: EXPERIMENTAL
Intervention: d,l-sotalol 80 mg twice daily
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: d,l-sotalol 120 mg twice daily
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: d,l-sotalol 160 mg twice daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 7847565

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure
Number of subjects: 542

Group type: COMPARATOR
Intervention: Unexposed women
Number of subjects: 542
Study: 1745318

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 9 g/24 hours
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 6 g/24 hours
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7082204

Group type: EXPERIMENTAL
Intervention: Lensectomy and anterior vitrectomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Discission and aspiration
Number of subjects: 27
Study: 31277184

Group type: EXPERIMENTAL
Intervention: 25G needle through the lateral crypt (group L, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 25G needle in a vertical approach (group C, n=30)
Number of subjects: 60